S-1/oxaliplatin (SOX) plus bevacizumab (Bev) as first line followed by S-1/irinotecan (IRIS) plus cetuximab (Cmab) as second line therapy in metastatic colorectal cancer (mCRC) (SOBIC trial) von Nakamoto, Y., Mikami, R., Umeki, M., Tokunaga, Y., Okumoto, T., Kawamura, T., Fujiwara, H., Doi, S., Noda, M., Tomita, N.

Volltext

Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer von Komatsu, Yoshito, Yuki, Satoshi, Sogabe, Susumu, Fukushima, Hiraku, Nakatsumi, Hiroshi, Kobayashi, Yoshimitsu, Iwanaga, Ichiro, Nakamura, Michio, Hatanaka, Kazuteru, Miyagishima, Takuto, Kudo, Mineo, Munakata, Masaki, Meguro, Takashi, Tateyama, Miki, Sakata, Yuh

Volltext

526PPHASE II STUDY OF COMBINED CHEMOTHERAPY WITH 5-WEEK CYCLES OF S-1 AND CPT-11 (IRIS) PLUS BEVACIZUMAB IN PATIENTS WITH METASTATIC COLON CANCER von Mizushima, T., Ide, Y., Murata, K., Ohashi, I., Yasumasa, K., Fukunaga, M., Takemoto, H., Tamagawa, H., Kato, T., Ikenaga, M., Hasegawa, J., Hata, T., Takemasa, I., Ikeda, M., Satoh, T., Yamamoto, H., Sekimoto, M., Nezu, R., Doki, Y., Mori, M.

Volltext

Phase Ii Study of Combined Chemotherapy with 5-Week Cycles of S-1 and Cpt-11 (Iris) Plus Bevacizumab in Patients with Metastatic Colon Cancer von Mizushima, T., Ide, Y., Murata, K., Ohashi, I., Yasumasa, K., Fukunaga, M., Takemoto, H., Tamagawa, H., Kato, T., Ikenaga, M., Hasegawa, J., Hata, T., Takemasa, I., Ikeda, M., Satoh, T., Yamamoto, H., Sekimoto, M., Nezu, R., Doki, Y., Mori, M.

Volltext

A randomized pilot study comparing safety and efficacy of irinotecan plus S-1 (IRIS) plus bevacizumab (BV) and modified (m) FOLFIRI plus BV in patients (pts) with metastatic colorectal cancer (mCRC): First report of T-CORE0702 von Kato, S., Andoh, H., Gamoh, M., Yamaguchi, T., Murakawa, Y., Sasaki, Y., Takahashi, S., Shimodaira, H., Yoshioka, T., Ishioka, C.

Volltext

Respondent-driven sampling in a study of drug users in New York City: notes from the field von McKnight, Courtney, Des Jarlais, Don, Bramson, Heidi, Tower, Lisa, Abdul-Quader, Abu S, Nemeth, Chris, Heckathorn, Douglas

Volltext

Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor von Yamazaki, Kentaro, Yuki, Satoshi, Oki, Eiji, Sano, Fumikazu, Makishima, Misako, Aoki, Kenichi, Hamano, Tetsutaro, Yamanaka, Takeharu

Volltext

Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer von Takaoka, Toshi, Kimura, Tetsuo, Shimoyama, Rai, Kawamoto, Shunji, Sakamoto, Kazuki, Goda, Fuminori, Miyamoto, Hiroshi, Negoro, Yuji, Tsuji, Akihito, Yoshizaki, Koji, Goji, Takahiro, Kitamura, Shinji, Yano, Hiromi, Okamoto, Koichi, Kimura, Masako, Okahisa, Toshiya, Muguruma, Naoki, Niitsu, Yoshiro, Takayama, Tetsuji

Volltext

A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer von Mizushima, Tsunekazu, Ide, Yoshito, Murata, Kohei, Ohashi, Ichiro, Yasumasa, Keigo, Fukunaga, Mutsumi, Takemoto, Hiroyoshi, Tamagawa, Hiroshi, Hasegawa, Junichi, Hata, Taishi, Takemasa, Ichiro, Ikeda, Masataka, Yamamoto, Hirofumi, Sekimoto, Mitsugu, Nezu, Riichiro, Doki, Yuichiro, Mori, Masaki

Volltext

Complete response of lung metastases from rectal cancer to combination first-line therapy of S-1 and irinotecan plus bevacizumab: A case report and review of the literature von SHIMAZAKI, JIRO, MOTOHASHI, GYO, NISHIDA, KIYOTAKA, TABUCHI, TAKANOBU, UBUKATA, HIDEYUKI, TABUCHI, TAKAFUMI

Volltext

Safety report of a phase II trial of irinotecan plus S-1 (IRIS) with cetuximab in patients with KRAS wild type of metastatic colorectal cancer: HGCSG0902 von Komatsu, Yoshito, Yuki, Satoshi, Kato, Takashi, Hosokawa, Ayumu, Iwanaga, Ichiro, Muto, Osamu, Hatanaka, Kazuteru, Nakamura, Michio, Tsuji, Yasushi, Sakata, Yuh

Volltext

A-093 Assessing Alkaline Phosphatase Reference Intervals Using Gamma-Glutamyl Transferase as a Surrogate for Normal Liver Function von Brown, H, Spies, N C, Farnsworth, C W

Volltext

Assessing Alkaline Phosphatase Reference Intervals Using Gamma-Glutamyl Transferase as a Surrogate for Normal Liver Function von Brown, Hannah, Spies, Nicholas, Farnsworth, Christopher

Volltext

A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer von Shimoyama, Rai, Kimura, Tetsuo, Takaoka, Toshi, Sakamoto, Kazuki, Kawamoto, Shunji, Yoshizaki, Koji, Negoro, Yuji, Goda, Fuminori, Tsuji, Akihito, Nakayama, Tsuyoshi, Miyamoto, Hiroshi, Takayama, Tetsuji, Niitsu, Yoshiro

Volltext

A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC) von Sadahiro, Sotaro, Suzuki, Toshiyuki, Tanaka, Akira, Okada, Kazutake, Saito, Gota, Miyakita, Hiroshi, Ogimi, Takashi, Chan, Lin Fung

Volltext

Treatment strategy for metastatic colorectal cancer (mCRC) treated with chemotherapy plus biological targeted agent: Is strategy with biological targeted agent based on the primary tumor lesion possible? von Sagawa, Tamotsu, Hamaguchi, Kyoko, Uemura, Naomi, Tamura, Fumito, Fujikawa, Koshi, Sato, Yasushi, Takahashi, Yasuo

Volltext

Relationship between socioeconomic status and prostate cancer (incidence, aggressiveness, treatment with curative intent, and mortality): a spatial analysis using population-based... von Khadhra, H. Ben, Saint, F., Trecherel, E., Lapôtre-Ledoux, B., Zerkly, S., Ganry, O.

Volltext

Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902—Comparison of administration interval in cetuximab treatment von Kondo, Tomohiro, Yuki, Satoshi, Kawamoto, Yasuyuki, Tsuji, Yasushi, Hosokawa, Ayumu, Nakamura, Michio, Muto, Osamu, Kato, Takashi, Iwanaga, Ichiro, Sato, Atsushi, Eto, Kazunori, Furukawa, Kouichi, Hayashi, Hideyuki, Tateyama, Miki, Takahashi, Yasuo, Sogabe, Susumu, Honda, Takuya, Sakata, Yuh, Komatsu, Yoshito

Volltext

Phase II trial of irinotecan, S-1, and bevacizumab (IRIS/Bev) combination chemotherapy as second line for advanced colorectal cancer (NCCSG04) von Takii, Yasumasa, Hurukawa, Kouichi, Maruyama, Satoshi, Yamazaki, Toshiyuki, Nishimura, Jun, Kawahara, Mikako, Tomiyama, Takemi, Akazawa, Kohei, Hatakeyama, Katsuyoshi

Volltext

Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial von Yuki, Satoshi, Komatsu, Yoshito, Fukushima, Hiraku, Sasaki, Takahide, Amano, Toraji, Miyagishima, Takuto, Hatanaka, Kazuteru, Nakamura, Michio, Tateyama, Miki, Sakata, Yuh

Volltext